Octagon & ScenPro Partner to Support FDA Legacy Data Conversion Project

The US Food and Drug Administration (FDA) recently awarded an Indefinite Delivery Indefinite Quantity (IDIQ) contract for “Legacy Data Conversion Services.” The contract was awarded to ScenPro, Inc., a woman-owned, small business based in Richardson, Texas. ScenPro is partnering with Octagon Research Solutions, Inc. on the performance of the contract. Ultimately the parties will involve the Clinical Data Interchange Standards Consortium (CDISC) to support this large-scale, complex project of converting legacy study data to an electronic standard format(s). CDISC is a global non-profit standards development organization that has established vendor-neutral, platform-independent standards to support the acquisition, exchange, submission, and archive of clinical research data and metadata.

The project addresses legacy data that resides in numerous different formats at FDA that must be converted into standard structures. ScenPro and Octagon will work with the agency to harmonize variable names and terminology while supporting the advancement of current standards and the development of new standardized values for domain data as required. ScenPro and Octagon will use their combined knowledge and experience to ensure accurate and efficient conversion of legacy data to facilitate answering important scientific and regulatory questions of interest to promote public health.

ScenPro, Inc. brings a team of knowledge analysts and domain experts to the project that will manage the project and provide critical technical expertise in modeling, data conversions and data management. Octagon Research Solutions, Inc.brings deep domain knowledge in clinical research data integration and standardization, proven data conversion and transformation methodologies and a broad capacity to support this large volume legacy data conversion project.

Michael Gately, president, ScenPro, Inc., added, “This milestone project highlights the critical nature of data standards in the evaluation of safety and efficacy of new therapies. We are excited about the opportunity to leverage our expertise to help the US FDA broaden their use of data standards throughout the agency.”

The initial Task Order was issued for this project and funded using American Recovery and Reinvestment Act (ARRA) funding. This task order supports the conversion of legacy clinical trial data across the Center for Drug Evaluation and Research (CDER), Center for Devices and Radiological Health (CDRH) and the Center for Biologics Evaluation and Research (CBER) to enable Comparative Effectiveness Research (CER) across vaccines, drugs and medical devices.

The conversion of these legacy data into standardized formats will enable the information to be processed with modern analytical software tools and to be merged with other, more recent, clinical study data. This larger collection will provide researchers with a broader view of how medical conditions affect different individuals and how they respond to various treatments. The requirement was awarded to a small business and was competitively full and open to all small business firms who wished to compete. The IDIQ contract contains a base ordering period of 5 years.